Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Syed A. Hussain et al.|The Lancet|2017Cited by 1.4k
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Stéphane Culine, Gwénaëlle Gravis et al.|European Urology|2020Cited by 246
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Alberto Bossi et al.|European Journal of Cancer|2023Cited by 156
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Danielle Carroll et al.|Nature Medicine|2021Cited by 115
Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysisChang-Hyun Lee, S. Fuentès, Tae-Ahn Jahng et al.|Journal of Neuro-Oncology|2015Cited by 44